Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

@article{Kaplan2011HyperactivationOM,
  title={Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells},
  author={Fred M. Kaplan and Yingkuan Shao and Melanie M. Mayberry and Andrew E Aplin},
  journal={Oncogene},
  year={2011},
  volume={30},
  pages={366-371}
}
Activating mutations in B-RAF and N-RAS occur in ∼60 and ∼15% of melanomas, respectively. The most common mutation in B-RAF is V600E, which activates B-RAF and the downstream MEK–ERK1/2 pathway. Thus, B-RAFV600E is a viable therapeutic target. PLX4720 is a selective inhibitor of mutant B-RAF and its analog, PLX4032, is currently undergoing clinical trials in melanoma. However, the effects of PLX4720 across the genotypic spectrum in melanoma remain unclear. Here, we describe that PLX4720… CONTINUE READING

Figures and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 63 CITATIONS, ESTIMATED 64% COVERAGE

SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

  • The Journal of biological chemistry
  • 2012
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

  • Supportive Care in Cancer
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation

  • The Journal of investigative dermatology
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2008
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Mutations of the BRAF gene in human cancer

VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Cytostatic activity of adenosine triphosphate - competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells

P Salerno, V DeFalco, +3 authors RE Schweppe
  • J Clin Endocrinol Metab
  • 2010
VIEW 1 EXCERPT